Myron M. Levine, Gordon Dougan, Michael F. Good, Margaret A. Liu, Gary J. Nabel, James P. Nataro, Rino Rappuoli, "New Generation Vaccines, Fourth Edition"
Informa Healthcare | ISBN: 1420060732 | December 9, 2009 | 1168 pages | PDF | 13.2 MB
Amazon Price: $454.28
The past 10 years have seen an expanded scientific and commercial interest in the potential of new vaccines. Scientific advances have created new tools for developing vaccines for diseases for which no vaccines exist. The complete genomic sequence of a pathogen provides a catalogue of potential vaccine components. Improved techniques of protein purification and peptide synthesis facilitate the identification, isolation, and engineering of candidate vaccines. Novel adjuvants, formulations, and delivery systems to induce an optimal immune response have been developed. Recombinant-DNA techniques facilitate the construction of live vaccines, live vectors, or nucleic acid vaccines into which a gene coding for the vaccine antigen can be cloned. The vaccine market is also growing rapidly, and by the year 2000 it is estimated that it will reach a sales volume twice or even three times that of the early 1990s. Average annual growth rates of the vaccine business could, in the next few years, be above 10 percent, which will obviously stimulate research and development in academic institutions and commercial pharmaceutical companies.
http://www.megaupload.com/?d=575FURGS